The results showed that loss of SOX9 significantly increased the sensitivity of cells to oxaliplatin, while gain of SOX9 decreased the drug sensitivity of CRC cells (Figures 2E–G and Supplementary Figure 2). Here, SOX9 is linked to colorectal carcinoma.